Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Asthma
Interventions
DRUG

BDP/FF/G

"BDP/FF/G is an extrafine single inhaler triple therapy available in two dosage strengths:~* Medium strength (MS) containing 100 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide);~* High strength (HS) containing 200 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide)."

Trial Locations (1)

Unknown

U.O. Clinica Psichiatrica e SPDC. Ospedale Policlinico S. Martino - IRCCS, Genova, Genoa

All Listed Sponsors
collaborator

Gesellschaft für Therapieforschung mbH

INDUSTRY

lead

Chiesi Italia

INDUSTRY

NCT06100042 - Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting | Biotech Hunter | Biotech Hunter